Adamax for Health & Longevity

Created on 11/05/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Adamax, a laboratory-made peptide sold online for memory and focus, has never been given to a person or an animal. Claims about it are borrowed from its parent peptide, Semax, or inferred from its chemistry; Semax’s modest evidence comes almost entirely from one Russian research network, mostly in ill people. Unmeasured hazards include signs of bleeding risk in rats, immune reaction risk from injected peptides, and unreliable product labels. (Full Review)

Protocol

Vendor-described intranasal regimen
100–300 mcg per nostril
Once or twice daily; no protocol from a clinical guideline, trial or product label exists
Vendor-described subcutaneous regimen
200–300 mcg once daily
For cognitive use; up to 300 mcg once or twice daily for neuroprotection
Time of day
Morning or early afternoon
Common recommendation, to keep the reported activating effects away from sleep onset
Time to effect
Acute focus effects
Within hours
Vendor-described; not measured for Adamax
Intranasal onset
5–15 minutes
Vendor-described; not measured for Adamax
Nerve-remodelling effects
2–4 weeks
Vendor-described; not measured for Adamax

Benefits

Contraindications
  • People with a bleeding disorder or on anticoagulation, including anyone in the weeks around surgery
  • Pregnant and breastfeeding women
  • People with uncontrolled hypertension, a recent heart attack (within 90 days) or New York Heart Association Class III–IV heart failure
  • People with a seizure disorder, an active psychotic illness or a stimulant use disorder
  • Anyone who cannot obtain an identity- and purity-verified product
Key Interactions
Theoretical (inferred from mechanism)
  • Anticoagulants and antiplatelet agents (warfarin, aspirin)
  • Psychostimulants (amphetamine, modafinil)
  • Serotonin-active medicines (sertraline, tramadol)
  • Other ACTH-derived peptides (melanotan II, bremelanotide)
  • Opioids and opioid antagonists (morphine, naltrexone)
  • Other research peptides (Selank, Noopept)
  • Copper and zinc supplements
  • Supplements with additive bleeding, stimulant or serotonin effects (fish oil, caffeine, St John’s wort)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Injury From an Unverified, Mislabelled Product; Paroxysmal Brain-Wave Activity After Injection
  • Speculative: Bleeding and Impaired Clotting; Immune Reaction to an Injected Peptide; Loss of Protective Activity From the Acetyl Cap; Stimulant-Like Overactivation and Abuse Potential; Local Irritation, Headache and Sleep Disruption

Monitoring

Marker Target Why
Platelet count 150–450 × 10⁹/L Bleeding safety check
aPTT 25–35 seconds Clotting-time safety check
Seated blood pressure Below 120/80 mmHg Safety check for raised blood pressure
Resting heart rate No established target; change from own pre-use baseline Safety check for palpitations and raised heart rate

Cadence: Baseline before starting; about 2 weeks after starting, at the end of a 4-week cycle, then before each subsequent cycle; immediate retesting if bruising, bleeding, palpitations or persistent headache appear

Qualitative Assessment

  • Time taken to fall asleep and sleep quality
  • Anxiety, restlessness or overstimulation, particularly in the first week and after any dose increase
  • Headache frequency and intensity
  • Nasal burning or irritation with intranasal use, and injection-site appearance with subcutaneous use
  • Focus and task completion on demanding work, recorded against a pre-use week
  • Appetite and body weight
  • Any visual symptom